SCHEMBL30464986

SCHEMBL30464986

CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 3/20 0.65
▸ MC5R P33032 2/20 0.65
▸ MC3R P41968 2/20 0.65
▸ MC1R Q01726 2/20 0.65
▸ C5AR1 P21730 2/20 0.59
▸ IL23R Q5VWK5 4/20 0.56
▸ CALCA P06881 2/20 0.56
▸ CTSL P07711 3/20 0.56
▸ CTSS P25774 3/20 0.56
▸ CTSK P43235 3/20 0.56
▸ CTSH P09668 1/20 0.55
▸ CXCR4 P61073 1/20 0.54
▸ NMBR P28336 1/20 0.54
▸ GRPR P30550 1/20 0.54
▸ GLP1R P43220 2/20 0.51
▸ GCGR P47871 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30464996 0.97 MC4R (0.67) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL30750450 0.96 MC4R (0.71) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL30750506 0.94 MC4R (0.73) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL29419548 0.89 MC4R (0.81) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL29352792 0.89 MC4R (0.81) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL22463810 0.89 MC4R (0.81) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL22463811 0.89 MC4R (0.81) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL29533175 0.88 MC4R (0.80) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL30427315 0.86 C5AR1 (0.72) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL30464995 0.86 IL23R (0.61) MC4RIL23R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11622994-B2 Therapy for vitiligo CLINUVEL PHARMACEUTICALS LIMITED (AU) 2023-04-11 — — US claimed
EP-3573645-B1 ALPHA-MSH ANALOGUES USED IN THE TREATMENT OF XERODERMA PIGMENTOSUM VALLAURIX MC S A R L (MC) 2024-03-13 — — EP disclosed
EP-3030256-B1 NDP-MSH FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS CLINUVEL PHARMACEUTICALS LTD (AU) 2024-01-24 — — EP disclosed
US-11622994-B2 Therapy for vitiligo CLINUVEL PHARMACEUTICALS LIMITED (AU) 2023-04-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11622994-B2 Therapy for vitiligo MC1R, MC3R, MC5R MC4R 4/4885MC5R 3/4885MC3R 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback